𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Stage IV-N: A favorable subset of children with metastatic neuroblastoma

✍ Scribed by Rosen, Eliot M. ;Cassady, J. Robert ;Frantz, Christopher N. ;Kretschmar, Cynthia S. ;Levey, Raphael ;Sallen, Stephen E.


Publisher
John Wiley and Sons
Year
1985
Tongue
English
Weight
436 KB
Volume
13
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis


Among children over 1 year of age with are long-term disease-free survivors, com-Evans Stage IV neuroblastoma, there appears pared with none of 40 patients with extranoto be a small group with a relatively favorable dal metastatic disease (p < 0.0002). Patients prognosis. These patients have extensive with only lymph node metastases (Stage "IV- lymph node metastases (cervical/axillary/tho-N") may have a biologically more favorable racic/abdominal/pelvic), but no extranodal tumor that is curable with conventional, inmetastases. Three of six such patients (50%) tensive multimodality therapy.


πŸ“œ SIMILAR VOLUMES


Treatment of children with stage IV favo
✍ Green, Daniel M.; Breslow, Norman E.; Evans, Ilonka; Moksness, Jami; D'Angio, Gi πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 491 KB πŸ‘ 2 views

The purpose of this study was to evaluate the effect of the sequential addition of doxorubicin and cyclophosphamide to the combination of vincristine and actinomycin D o n the relapse-free survival of children with stage IV/favorable histology Wilms tumor. We reviewed the clinical courses of all ran

Radiotherapy omitted in the treatment of
✍ Pachnis, A.; Pritchard, J.; Gaze, M.; Levitt, G.; Michalski, A. πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 54 KB πŸ‘ 3 views

Background. Current treatment of stage III favorable histology (FH) Wilms tumor is surgery, radiotherapy to residual disease, and ''triple'' chemotherapy (vincristine, dactinomycin, and doxorubicin) for 12 months. This study tests the hypothesis that some stage III patients, especially very young ch

Prognostic value of bcl-6, CD10 and CD38
✍ Maurilio Ponzoni; AndrΓ©s J.M. Ferreri; Giancarlo Pruneri; Barbara Pozzi; Stefani πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 French βš– 76 KB

## Abstract bcl‐6, CD10 and CD38 are useful markers for identifying 2 molecularly and prognostically distinct profiles of diffuse large B‐cell lymphomas (LCLs), defined as germinal‐center B‐like and activated B‐like. We investigated the prognostic role of bcl‐6, CD10 and CD38 immunoreactivity in 10